FINWIRES · TerminalLIVE
FINWIRES

$PTGX

3 stories mentioning PTGXUpdated 41d ago

Every FINWIRES story that references PTGX, newest first.

Insider Trading

Protagonist Therapeutics Insider Sold Shares Worth $7,509,000, According to a Recent SEC Filing

Dinesh V Patel Ph.D., Director, President and Chief Executive Officer, on May 12, 2026, sold 75,000 shares in Protagonist Therapeutics (PTGX) for $7,509,000. Following the Form 4 filing with the SEC, Patel has control over a total of 523,478 common shares of the company, with 523,478 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1377121/000110465926059591/xslF345X05/tm2614444-1_4seq1.xml

$PTGX
Wire

Wedbush Adjusts Price Target on Protagonist Therapeutics to $118 From $112, Maintains Outperform Rating

Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $116.31, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $104.30, Change: $+5.09, Percent Change: +5.13%

$PTGX
Wire

Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical

Protagonist Therapeutics (PTGX) exercised its right to opt out of the 50/50 US profit and loss sharing arrangement under its global license and collaboration agreement with Takeda Pharmaceutical (TAK) for rusfertide, Protagonist Therapeutics said Tuesday.As a result, Protagonist Therapeutics will be eligible to receive up to $400 million in opt-out payments.The company will also be entitled to a $75 million milestone payment upon rusfertide's approval in the US and up to $975 million in other milestone payments and tiered royalties on net sales, according to the statement.Takeda Pharmaceutical now holds exclusive development and commercialization rights to rusfertide in the US.Rusfertide is under FDA Priority Review in the US for the treatment of adult patients with polycythemia vera, Protagonist Therapeutics said.Price: $99.31, Change: $+0.84, Percent Change: +0.85%

$PTGX$TAK

Track with the FINWIRES app suite

FolioX
FolioX
Track PTGX in your portfolio
WheelAI
WheelAI
Analyze PTGX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on PTGX